± Participação do Dr. Simon Campbell e do Dr. Paul Leeson

± Não haverá apresentação de trabalhos.

± Inscrições até 20 de janeiro de 2006.

± Serão concedidas 10 bolsas de isenção de inscrição para alunos de graduação da UFRJ inscritos até 23/12/2005.

± Para se candidatar ao auxílio, é necessário o pré-pagamento da inscrição, que será concedido ao longo do evento.

± ATENÇÃO PARTICIPANTES DE FORA DO ESTADO DO RIO DE JANEIRO: Serão concedidas 40 bolsas no valor da inscrição para participar do evento. << Clique e saiba mais >>

± Todas as Bolsas serão co-patrocinadas pela Royal Society of Chemistry (UK) e pela Sociedade Brasileira de Química (Brasil).
UFRJ UFRJ
FACULDADE DE FARMÁCIA Faculdade de Farmácia
LASSBio

» Histórico
» Entidades Promotoras
» Inscrições
» Programa
» Cursos e Conferêcias
» Prof. Estrangeiros
» Informações Adicionais
» Apoio
» Comissão Organizadora
» Contato
» Home
13 a 17 de fevereiro de 2006

CURRICULUM VITAE DOS PROFESSORES ESTRANGEIROS

Biographical Summary for Simon F. Campbell, PhD, FRS


Simon Campbell is a synthetic organic chemist who received his BSc. (1962) and PhD (1965) degrees from Birmingham University in the UK. He then carried out postdoctoral research in Birmingham, Chile and at Stanford University with W.S.Johnson, before being appointed Visiting Professor at the Universidade de Sao Paulo, Brasil in 1970.

In 1972, Dr. Campbell joined Pfizer Central Research, Sandwich, as a medicinal chemist, and he retired from Pfizer in October 1998 as Senior Vice President for World-wide Discovery and Medicinal R&D Europe. He has co-authored over 110 publications and patents, and was a key member of the research teams that discovered doxazosin (CarduraTM) and amlodipine (NorvascTM). Both of these novel medicines became the leading agents worldwide in their therapeutic class. In addition, he was senior author on the research proposal that led to sildenafil (ViagraTM), the first oral treatment for Male Erectile Dysfunction.

Dr. Campbell's scientific contributions have been recognised by the Royal Society of Chemistry Award for Medicinal Chemistry (1989), the Herschberg Award from the American Chemical Society (1997), and the Industry Research Institute (US) Achievement Award (1997). He was elected Fellow of the Royal Society (1999) and Fellow of the Academy of Medical Sciences (2002) and was admitted to the degree of Doctor of Science honoris causa by the University of Kent at Canterbury (1999) and the University of Birmingham (2004). Dr. Campbell has served on various professional and research bodies including SERC Organic Chemistry Sub-Committee, Science Board, LINK Asymmetric Synthesis, ABPI R&D Committee, Chemistry RAE Panel (2001) and as Visiting Professor at the University of Leeds and Birkbeck College. He also served as Chair of the Expert Scientific Advisory Committee for the Medicines for Malaria Venture (Geneva, 1999-2003) and as a member of the British Petroleum Technology Advisory Council (2000-04). Dr Campbell is a Fellow of the Royal Society of Chemistry, and a member of the American Chemical Society.

Currently, Dr. Campbell is a member of the SABs of Astex (Cambridge), Chroma (Oxford), DanioLabs (Cambridge) Inpharmatica (London), Merlion (Singapore) S*Bio (Singapore), Sunesis (San Francisco), and the Conway Institute (Dublin). He acts as consultant to Abingworth Management (London) Almirall (Barcelona) and Jerini (Berlin). He is President of the Royal Society of Chemistry, serves on the Council of the University of Kent and the Advisory Council for Save British Science.

 
Desenvolvido por: Cúpula Informática